EMA Recommends Extension of Indications for Pirtobrutinib By Ogkologos - April 24, 2025 613 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of patients with relapsed or refractory chronic lymphocytic leukaemia Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR Pumpkin Season! October 27, 2020 Addressing Cancer Disparities and New Research in Treating HPV-Positive Head and... March 31, 2022 COVID-19: “We’re having to rebuild and adapt because of coronavirus” July 15, 2020 FDA Granted Accelerated Approval to Tazemetostat for Follicular Lymphoma June 22, 2020 Load more HOT NEWS Patient Guide in Bladder Cancer Now Available Also in Italian When Breast Cancer Patient Comes Into His Shop, Barber Shaves His... A Subset of Patients with NSCLC Respond Poorly to the COVID-19... Two-Step Approach Might Be An Alternative to Standard Three-Step Approach of...
